MedTrace Logo

Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

NCT03373461 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2023-01-30

Study results available
· View outcomes & findings →

Summary

Efficacy and safety of LNP023 in IgAN patients

Conditions

Interventions

DRUG

LNP023

LNP023 5, 25, 100 mg capsles

OTHER

Placebo

Matching placebo to LNP023

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-07
Primary Completion
2020-12-29
Completion
2021-06-22
FDA Drug
Yes

Countries

  • Argentina
  • Australia
  • Belgium
  • Brazil
  • China
  • Colombia
  • Czechia
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong
  • India
  • Israel
  • Japan
  • Malaysia
  • Netherlands
  • Norway
  • Singapore
  • South Korea
  • Sweden
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03373461 on ClinicalTrials.gov